UK markets close in 6 hours 44 minutes

Stoke Therapeutics, Inc. (STOK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.17+3.88 (+37.71%)
At close: 04:00PM EDT
14.02 -0.15 (-1.06%)
Pre-market: 05:38AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.29
Open11.20
Bid11.60 x 100
Ask14.18 x 200
Day's range10.36 - 16.40
52-week range3.35 - 16.40
Volume17,125,290
Avg. volume866,686
Market cap650.661M
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)-2.38
Earnings date02 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est23.67
  • Business Wire

    Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

    BEDFORD, Mass., March 28, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730

  • Zacks

    Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

    Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

  • Business Wire

    Stoke Therapeutics Announces Proposed Public Offering

    BEDFORD, Mass., March 26, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an addi